Nothing is certain but death and taxanes.

Taxanes have long been key players in the treatment of gyn and lung cancers and, more recently, were a noteworthy addition in the FLOT regimen  for gastric cancer. A recent phase 2 trial aims to put them on the map for recurrent anal cancer, with a modified regimen of docetaxel / cisplatin / 5FU (DCF) establishing the largest reported rate of progression-free survival at one year at 31/66 (47%). | Kim, Lancet Oncol